ImmunityBio’s (IBRX) “Buy” Rating Reiterated at D. Boral Capital
D. Boral Capital reissued their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report released on Thursday,Benzinga reports. The brokerage currently has a $30.00 price target on the stock. Other equities research analysts have also recently issued reports about the company. BTIG Research started coverage on ImmunityBio in a report […]
D. Boral Capital reissued their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report released on Thursday,Benzinga reports. The brokerage currently has a $30.00 price target on the stock. Other equities research analysts have also recently issued reports about the company. BTIG Research started coverage on ImmunityBio in a report […]
